Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Iowa Hepcludex Coverage Policy | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.06.34

    Hepcludex Coverage for Chronic Hepatitis Delta Virus Infection

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.06.34 alerts

    Get alerted when Policy 05.06.34 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage of Hepcludex (bulevirtide-gmod) for adults with chronic hepatitis delta virus infection when documented clinical, laboratory, prescriber, and liver-disease criteria are met.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyHepcludex Coverage for Chronic Hepatitis Delta Virus Infection
    Policy CodePolicy 05.06.34
    Change TypeNo material change
    Effective DateSep 14, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming chronic HDV infection, pretreatment elevated ALT, and no current or previous decompensated liver disease.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsInitial authorization period
    12 monthsContinuation authorization period
    8.5 mg dailyFDA-recommended dosing
    1 vial/dayStandard quantity limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3
    Required chronic HDV elements

    Coverage Criteria

    Initial Therapy

    Covered when all of the following are met:

    Initial therapy

    • Confirmed chronic HDV infection

      • Positive anti-HDV antibody: Positive serum anti-HDV antibody result.positive
      • Recent positive HDV RNA: Positive polymerase chain reaction result for HDV RNA within the past 6 months.within the past 6 months
      • Chronic infection duration: The HDV infection has been present for longer than 6 months.> 6 months
    • Pretreatment ALT elevation: Member has a pretreatment elevated serum alanine aminotransferase (ALT) level.elevated serum ALT
    • No decompensated liver disease: Member has no current or previous decompensated liver disease, including coagulopathy, hepatic encephalopathy, ascites, or esophageal variceal hemorrhage.none current or previous

    Continuation Therapy

    Continuation coverage may be granted when the member achieves or maintains a positive clinical response:

    Continuation therapy

    • At least one positive clinical response

      • Decreased HDV RNA: HDV RNA level has decreased.decreased HDV RNA level
      • ALT normalization: Alanine aminotransferase (ALT) has normalized.ALT normalization

    Coverage is not available for members with current or previous decompensated liver disease, including coagulopathy, hepatic encephalopathy, ascites, or esophageal variceal hemorrhage.

    Hepcludex is considered not medically necessary for members who do not meet the policy criteria.

    Procedures, Billing, and Policy Parameters

    Procedures and Billing CodesHCPCS
    J3490Unclassified drugs
    J3590Unclassified biologics
    HDV RNA PCR Recency
    Required resultPositive HDV RNA polymerase chain reaction result
    Testing timeframeWithin the past 6 months
    Applies toConfirmation of chronic HDV infection
    HDV Infection Duration
    Required durationHDV infection present for longer than 6 months
    Threshold> 6 months
    Applies toConfirmation of chronic HDV infection

    Prior Authorization and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Hepcludex treatment of chronic HDV infection in adults without cirrhosis or with compensated cirrhosis. Submit evidence that all clinical criteria are met, including confirmed chronic HDV infection, a pretreatment elevated serum ALT level, and no current or previous decompensated liver disease.

    • Treatment is subject to the policy’s initial-approval criteria.
    • Authorization may be granted for 12 months when all requirements are satisfied.
    Documentation Required

    Required Clinical Documentation

    Submit chart notes or medical-record documentation to support the prior authorization review and establish the member’s HDV infection and liver-disease status.

    • Documentation demonstrating hepatitis D virus infection.
    • Documentation supporting the absence of decompensated liver disease.

    Clinical Background

    Hepcludex (bulevirtide-gmod) is indicated for the treatment of chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis. The indication received accelerated approval based on decreases in HDV RNA and ALT normalization; improvement in disease-related clinical outcomes has not been established.

    Policy Definitions

    Covered HDV Population
    PopulationAdults with chronic hepatitis delta virus infection
    Without cirrhosisCovered
    With compensated cirrhosisCovered
    Chronic HDV Infection Confirmation
    AntibodyPositive serum anti-HDV antibody result
    HDV RNA PCRPositive result within the past 6 months
    DurationHDV infection present for greater than 6 months

    Initial Therapy Authorization

    Initial Therapy — 12-Month Authorization

    Authorization of 12 months may be granted when all initial-approval criteria are met:

    Initial therapy

    • Confirmed chronic HDV infection

      • Positive anti-HDV antibody: Positive serum anti-HDV antibody result.positive
      • Recent positive HDV RNA: Positive polymerase chain reaction result for HDV RNA within the past 6 months.within the past 6 months

    Continuation Therapy Authorization

    Continuation Therapy — 12-Month Renewal

    Authorization of 12 months may be granted for continued treatment when the member achieves or maintains a positive clinical response:

    Continuation therapy

    • At least one positive clinical response

      • Decreased HDV RNA: HDV RNA level has decreased.decreased HDV RNA level
      • ALT normalization: Alanine aminotransferase (ALT) has normalized.ALT normalization

    Hepcludex Quantity Limit

    Hepcludex Quantity Limit
    MedicationHepcludex (bulevirtide-gmod) 8.5 mg subcutaneous injection
    Quantity limit1 vial
    Limit frequencyPer day
    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyHepcludex Coverage for Chronic Hepatitis Delta Virus Infection
    Policy CodePolicy 05.06.34
    Change TypeNo material change
    Effective DateSep 14, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming chronic HDV infection, pretreatment elevated ALT, and no current or previous decompensated liver disease.
    SourceLink
    On This Page
    Coverage CriteriaProcedures, Billing, and Policy ParametersPrior Authorization and DocumentationClinical BackgroundPolicy DefinitionsInitial Therapy AuthorizationContinuation Therapy AuthorizationHepcludex Quantity Limit
    Hepcludex Standard Quantity Limit
    MedicationHepcludex (bulevirtide-gmod) 8.5 mg subcutaneous injection
    Standard quantity limit1 vial
    FrequencyPer day
    Hepcludex FDA-Recommended Dose
    Dose8.5 mg
    RouteSubcutaneously
    FrequencyOnce daily
    Prior Authorization

    Qualified Prescriber or Consultant Required

    Hepcludex must be prescribed by or in consultation with a provider experienced in managing hepatitis D virus infection (HDV).

    • Hepatologist
    • Gastroenterologist
    • Infectious disease provider
    Denial Risk

    Insufficient Confirmation of Chronic HDV Infection

    Coverage may be denied when chronic HDV infection is not confirmed by all required elements.

    • Positive serum anti-HDV antibody result.
    • Positive HDV RNA polymerase chain reaction result obtained within the past 6 months.
    • Evidence that the HDV infection has been present for more than 6 months.
    Denial Risk

    No Pretreatment ALT Elevation

    Coverage may be denied when the member does not have a pretreatment elevated serum alanine aminotransferase (ALT) level.

    • A pretreatment serum ALT elevation is required for initial approval.
    Denial Risk

    Decompensated Liver Disease

    Coverage may be denied for members with current or previous decompensated liver disease.

    • Examples include coagulopathy, hepatic encephalopathy, ascites, or esophageal variceal hemorrhage.
    • The policy permits treatment for adults without cirrhosis or with compensated cirrhosis.
    Denial Risk

    Criteria Not Met

    Hepcludex is considered not medically necessary for members who do not meet the policy criteria for initial approval.

    • All applicable coverage requirements must be satisfied before authorization can be approved.
    Decompensated Liver Disease
    CoagulopathyIncluded as decompensated liver disease
    Hepatic encephalopathyIncluded as decompensated liver disease
    AscitesIncluded as decompensated liver disease
    Esophageal variceal hemorrhageIncluded as decompensated liver disease
    Chronic infection duration:
    The HDV infection has been present for longer than 6 months.
    > 6 months
  1. Pretreatment ALT elevation: Member has a pretreatment elevated serum alanine aminotransferase (ALT) level.elevated serum ALT
  2. No decompensated liver disease: Member has no current or previous decompensated liver disease, including coagulopathy, hepatic encephalopathy, ascites, or esophageal variceal hemorrhage.none current or previous